| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8486038 | Vaccine | 2018 | 11 Pages |
Abstract
The cost-effectiveness of QIV varied between communities due to differences in influenza epidemiology, comorbidities, and unit costs. Whether TIV or QIV is the most cost-effective alternative heavily depends on influenza B burden among subpopulations targeted for vaccination in addition to country-specific willingness-to-pay thresholds and budgetary impact.
Keywords
TIVQIVDynamic transmission modelTrivalentNMBICERLMICsQALYSARIBSWTPPSAInfluenzaCost-effectivenessprobabilistic sensitivity analysisWillingness-to-payGross domestic productGDPWorld Health Organizationquality-adjusted life yearNet monetary benefitIncremental cost-effectiveness ratioTrivalent influenza vaccineVaccinationhuman immunodeficiency virusHIVQuadrivalentWHO
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Pieter T. de Boer, Joel K. Kelso, Nilimesh Halder, Thi-Phuong-Lan Nguyen, Jocelyn Moyes, Cheryl Cohen, Ian G. Barr, Maarten J. Postma, George J. Milne,